Stocks › COGT
Cogent Biosciences, Inc.
COGT·Nasdaq·
United States·USD
United States·USD$30.38
-0.49 (-1.59%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
COGT
Cogent Biosciences, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
COGTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of COGT by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Christopher L. JacobsHouse · R · NY |
COGTCogent Biosciences, Inc. · Stock |
Purchase $1,001 - $15,000 |
Jan 20, 2023 | Dec 12, 2022 | Filing ↗ |
Whale Activity
Position changes in COGT reported for 2026-06-30 by 15 tracked institutional filers
- Increased4
- New0
- Held1
- Decreased5
- Closed0
- No prior filing5
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 17.4M | $671.5M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.1M | $312.4M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.4M | $286.9M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 996.2K | $38.6M | increased |
| D. E. Shaw & Co., Inc. | 922.5K | $35.7M | decreased |
| MILLENNIUM MANAGEMENT LLC | 907.7K | $35.1M | decreased |
| CITADEL ADVISORS LLC | 849.7K | $32.9M | decreased |
| Point72 Asset Management, L.P. | 744.2K | $28.8M | decreased |
| Affinity Asset Advisors, LLC | 450.0K | $17.4M | — |
| Affinity Asset Advisors, LLC | 11.0M | $13.7M | — |
| Atika Capital Management LLC | 272.0K | $10.5M | — |
| Seven Fleet Capital Management LP | 147.5K | $5.7M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by COGT insiders, by quarter · Form 4
Recent Insider Transactions
498 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Morris ArleneDirector · Director | Sale | −42.3K | $37.09 | $1.6M | Aug 27, 2026 | Form 4 ↗ |
| Morris ArleneDirector · Director | Sale | −3,161 | $37.54 | $119K | Aug 27, 2026 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Gift | +160.0K | $0.00 | $0 | May 19, 2026 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Gift | −160.0K | $0.00 | $0 | May 19, 2026 | Form 4 ↗ |
| Fairmount Funds Management LLCDirector | Sale | −7.0M | $34.66 | $242.6M | Mar 31, 2026 | Form 4 ↗ |
| Fairmount Funds Management LLCDirector | Conversion | +7.0M | — | — | Mar 31, 2026 | Form 4 ↗ |
| Fairmount Funds Management LLCDirector | Sale | −3.5M | $36.40 | $127.4M | Jan 22, 2026 | Form 4 ↗ |
| Kearns EvanChief Legal Officer | Sale | −65.0K | $38.70 | $2.5M | Dec 26, 2025 | Form 4 ↗ |
| Green John L.Chief Financial Officer | Sale | −77.0K | $38.68 | $3.0M | Dec 26, 2025 | Form 4 ↗ |
| Sachs JessicaChief Medical Officer | Sale | −82.6K | $38.70 | $3.2M | Dec 26, 2025 | Form 4 ↗ |
| Robinson John EdwardChief Scientific Officer | Sale | −90.0K | $38.74 | $3.5M | Dec 26, 2025 | Form 4 ↗ |
| Robinson John EdwardChief Scientific Officer | Tax withholding | −140.0K | $39.45 | $5.5M | Dec 17, 2025 | Form 4 ↗ |
| Robinson John EdwardChief Scientific Officer | Grant / award | +320.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Robinson John EdwardChief Scientific Officer | Grant / award | +50.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Tax withholding | −367.5K | $39.45 | $14.5M | Dec 17, 2025 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Grant / award | +840.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Robbins Andrew RPresident and CEO · Director | Grant / award | +185.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Pinnow ColeChief Commercial Officer | Tax withholding | −94.8K | $39.45 | $3.7M | Dec 17, 2025 | Form 4 ↗ |
| Pinnow ColeChief Commercial Officer | Grant / award | +214.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
| Pinnow ColeChief Commercial Officer | Grant / award | +50.0K | $0.00 | $0 | Dec 17, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding COGT · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.2M | $199.6M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 4.3M | $165.6M | 0.20% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.7M | $144.1M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 3.2M | $122.8M | 1.14% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 2.5M | $97.7M | 1.11% | Jul 31, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 2.4M | $91.3M | 0.13% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.0M | $75.8M | 0.08% | Jun 30, 2026 |
| Fidelity OTC Portfolio Fidelity Securities Fund | 1.9M | $72.9M | 0.17% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 1.8M | $71.4M | 3.25% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.8M | $70.9M | 0.21% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list COGT's shares (CUSIP 19240Q201), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- James E. FlynnSCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
Aug 13, 2026 · ↗ - Deerfield Partners, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
Aug 13, 2026 · ↗ - Deerfield Management Company, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
Aug 13, 2026 · ↗ - Deerfield Mgmt, L.P.SCHEDULE 13G/A · passive (13G) · 5.0M shares2.9%
Aug 13, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 8.7M shares5.1%
Jul 31, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 13.6M shares8.0%
Jul 27, 2026 · ↗ - James E. FlynnSCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
May 14, 2026 · ↗ - Deerfield Partners, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
May 14, 2026 · ↗ - Deerfield Management Company, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
May 14, 2026 · ↗ - Deerfield Mgmt, L.P.SCHEDULE 13G/A · passive (13G) · 9.0M shares5.3%
May 14, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Cogent Biosciences, Inc. as client
No lobbying filings found naming Cogent Biosciences, Inc. as the client.
Government Contracts
Federal awards to Cogent Biosciences, Inc. · USAspending
No federal contract awards found for Cogent Biosciences, Inc..
U.S. Patents
Recent USPTO applications naming Cogent Biosciences, Inc.
No USPTO patent applications found for Cogent Biosciences, Inc..
Annual Financials
From COGT's 10-K filings · XBRL
No annual XBRL figures on record for COGT. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-4Reverse splitNov 9, 2020
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
About Cogent Biosciences, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersWALTHAM, MA
IncorporatedDE
SEC CIK0001622229 ↗
Former namesUnum Therapeutics Inc., Unum Therapeutics, Inc.